<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03002766</url>
  </required_header>
  <id_info>
    <org_study_id>67/13</org_study_id>
    <nct_id>NCT03002766</nct_id>
  </id_info>
  <brief_title>Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast</brief_title>
  <acronym>DCIS</acronym>
  <official_title>Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By this non-randomized prospective study, it's evaluated the outcome of patients underwent
      BCS for DCIS at whom an established score system to address adjuvant therapies have been
      prospectively applied, according to the wideness of free margins.

      Between March 2000 and April 2006, 224 patients were enrolled and followed within the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumor Recurrence (IBTR)</measure>
    <time_frame>six years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contralateral breast cancer (CBC)</measure>
    <time_frame>six years</time_frame>
    <description>the side effects of radiotherapy may outweigh the reduction in the risk of IBTR</description>
  </secondary_outcome>
  <enrollment type="Actual">224</enrollment>
  <condition>Carcinoma Breast</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast conservative surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18 years;

          -  female candidate to breast conservative surgery

        Exclusion Criteria:

          -  female with previous omolateral or controlateral breast cancer;

          -  female with previous radiotherapy (RT).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimiliano Gennaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale Tumori</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massimiliano Gennaro</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J AM Stat Assoc 53:457-481, 1958.</citation>
  </reference>
  <results_reference>
    <citation>Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998 Feb;16(2):441-52.</citation>
    <PMID>9469327</PMID>
  </results_reference>
  <results_reference>
    <citation>Donker M, Litière S, Werutsky G, Julien JP, Fentiman IS, Agresti R, Rouanet P, de Lara CT, Bartelink H, Duez N, Rutgers EJ, Bijker N. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013 Nov 10;31(32):4054-9. doi: 10.1200/JCO.2013.49.5077. Epub 2013 Sep 16.</citation>
    <PMID>24043739</PMID>
  </results_reference>
  <results_reference>
    <citation>Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, Karlsson P, Anderson H, Emdin S. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008 Mar 10;26(8):1247-52. doi: 10.1200/JCO.2007.12.7969. Epub 2008 Feb 4.</citation>
    <PMID>18250350</PMID>
  </results_reference>
  <results_reference>
    <citation>Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162-77. doi: 10.1093/jncimonographs/lgq039. Review.</citation>
    <PMID>20956824</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011 Jan;12(1):21-9. doi: 10.1016/S1470-2045(10)70266-7. Epub 2010 Dec 7.</citation>
    <PMID>21145284</PMID>
  </results_reference>
  <results_reference>
    <citation>Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999 Jun 12;353(9169):1993-2000.</citation>
    <PMID>10376613</PMID>
  </results_reference>
  <results_reference>
    <citation>Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016 Feb 27;387(10021):849-56. doi: 10.1016/S0140-6736(15)01168-X. Epub 2015 Dec 11.</citation>
    <PMID>26686957</PMID>
  </results_reference>
  <results_reference>
    <citation>Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.</citation>
    <PMID>26686313</PMID>
  </results_reference>
  <results_reference>
    <citation>Povoski SP, Jimenez RE, Wang WP, Xu RX. Standardized and reproducible methodology for the comprehensive and systematic assessment of surgical resection margins during breast-conserving surgery for invasive breast cancer. BMC Cancer. 2009 Jul 27;9:254. doi: 10.1186/1471-2407-9-254.</citation>
    <PMID>19635166</PMID>
  </results_reference>
  <results_reference>
    <citation>Rizzo M, Iyengar R, Gabram SG, Park J, Birdsong G, Chandler KL, Mosunjac MB. The effects of additional tumor cavity sampling at the time of breast-conserving surgery on final margin status, volume of resection, and pathologist workload. Ann Surg Oncol. 2010 Jan;17(1):228-34. doi: 10.1245/s10434-009-0643-x. Epub 2009 Jul 28.</citation>
    <PMID>19636625</PMID>
  </results_reference>
  <results_reference>
    <citation>Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163-70.</citation>
    <PMID>5910392</PMID>
  </results_reference>
  <results_reference>
    <citation>EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group, Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006 Jul 20;24(21):3381-7. Epub 2006 Jun 26.</citation>
    <PMID>16801628</PMID>
  </results_reference>
  <results_reference>
    <citation>Rutgers EJ; EUSOMA Consensus Group. Quality control in the locoregional treatment of breast cancer. Eur J Cancer. 2001 Mar;37(4):447-53.</citation>
    <PMID>11267852</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwartz GF, Veronesi U, Clough KB, Dixon JM, Fentiman IS, Heywang-Köbrunner SH, Holland R, Hughes KS, Mansel RE, Margolese R, Mendelson EB, Olivotto IA, Palazzo JP, Solin LJ; Consensus Conference Committee. Consensus conference on breast conservation. J Am Coll Surg. 2006 Aug;203(2):198-207.</citation>
    <PMID>16864033</PMID>
  </results_reference>
  <results_reference>
    <citation>Rutqvist LE, Rose C, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in breast cancer. Acta Oncol. 2003;42(5-6):532-45. Review.</citation>
    <PMID>14596511</PMID>
  </results_reference>
  <results_reference>
    <citation>Healy C, Allen RJ Sr. The evolution of perforator flap breast reconstruction: twenty years after the first DIEP flap. J Reconstr Microsurg. 2014 Feb;30(2):121-5. doi: 10.1055/s-0033-1357272. Epub 2013 Oct 25. Review.</citation>
    <PMID>24163223</PMID>
  </results_reference>
  <results_reference>
    <citation>Kasem A, Wazir U, Headon H, Mokbel K. Breast lipofilling: a review of current practice. Arch Plast Surg. 2015 Mar;42(2):126-30. doi: 10.5999/aps.2015.42.2.126. Epub 2015 Mar 16. Review.</citation>
    <PMID>25798382</PMID>
  </results_reference>
  <results_reference>
    <citation>Gennaro M, Ferraris C, Guida V, Tomasic G, Carcangiu ML, Greco M. Conservative surgery in breast cancer. Significance of resection margins. Breast. 2001 Oct;10(5):432-7.</citation>
    <PMID>14965620</PMID>
  </results_reference>
  <results_reference>
    <citation>Macdonald HR, Silverstein MJ, Lee LA, Ye W, Sanghavi P, Holmes DR, Silberman H, Lagios M. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast. Am J Surg. 2006 Oct;192(4):420-2.</citation>
    <PMID>16978941</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Zee KJ, Liberman L, Samli B, Tran KN, McCormick B, Petrek JA, Rosen PP, Borgen PI. Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer. 1999 Nov 1;86(9):1757-67.</citation>
    <PMID>10547549</PMID>
  </results_reference>
  <results_reference>
    <citation>Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999 Aug 1;86(3):429-38.</citation>
    <PMID>10430251</PMID>
  </results_reference>
  <results_reference>
    <citation>Simpson PT, Reis-Filho JS, Lambros MB, Jones C, Steele D, Mackay A, Iravani M, Fenwick K, Dexter T, Jones A, Reid L, Da Silva L, Shin SJ, Hardisson D, Ashworth A, Schmitt FC, Palacios J, Lakhani SR. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol. 2008 Jul;215(3):231-44. doi: 10.1002/path.2358.</citation>
    <PMID>18473330</PMID>
  </results_reference>
  <results_reference>
    <citation>Lesurf R, Aure MR, Mørk HH, Vitelli V; Oslo Breast Cancer Research Consortium (OSBREAC), Lundgren S, Børresen-Dale AL, Kristensen V, Wärnberg F, Hallett M, Sørlie T. Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. Cell Rep. 2016 Jul 26;16(4):1166-1179. doi: 10.1016/j.celrep.2016.06.051. Epub 2016 Jul 7.</citation>
    <PMID>27396337</PMID>
  </results_reference>
  <results_reference>
    <citation>Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, Poller DN. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996 Jun 1;77(11):2267-74.</citation>
    <PMID>8635094</PMID>
  </results_reference>
  <results_reference>
    <citation>Silverstein MJ, Lagios MD. Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index. Breast J. 2015 Mar-Apr;21(2):127-32. doi: 10.1111/tbj.12368. Epub 2015 Jan 20.</citation>
    <PMID>25600630</PMID>
  </results_reference>
  <results_reference>
    <citation>Sagara Y, Freedman RA, Vaz-Luis I, Mallory MA, Wong SM, Aydogan F, DeSantis S, Barry WT, Golshan M. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. J Clin Oncol. 2016 Apr 10;34(11):1190-6. doi: 10.1200/JCO.2015.65.1869. Epub 2016 Feb 1.</citation>
    <PMID>26834064</PMID>
  </results_reference>
  <results_reference>
    <citation>Benson JR, Jatoi I, Toi M. Treatment of low-risk ductal carcinoma in situ: is nothing better than something? Lancet Oncol. 2016 Oct;17(10):e442-e451. doi: 10.1016/S1470-2045(16)30367-9. Review.</citation>
    <PMID>27733270</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2016</study_first_posted>
  <last_update_submitted>December 21, 2016</last_update_submitted>
  <last_update_submitted_qc>December 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

